UseGrants

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

National Institutes of HealthAmount not specifiedDue Feb 20, 2029
View & apply on Grants.gov →

This NIH HEAL Initiative UG3/UH3 cooperative agreement funds preclinical optimization and development of safe, non-addictive small-molecule and biologic therapeutics for treating pain, advancing ca…

Deadline
Feb 20, 2029
Posted
Jun 16, 2026
Award amount
Amount not specified
Focus areas
Health

Don’t miss this deadline

We’ll email you before Feb 20, 2029 so you have time to apply.

In plain English

This NIH HEAL Initiative UG3/UH3 cooperative agreement funds preclinical optimization and development of safe, non-addictive small-molecule and biologic therapeutics for treating pain, advancing candidates toward Phase II trials. Applicants must already have a promising lead candidate, a strong biological rationale, and established assays. Foreign organizations and foreign components of U.S. organizations are not eligible to apply.

AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.

Who can apply

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

About this grant

The purpose of this Notice of Funding Opportunity (NOFO) is to support the preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics for the treatment of pain. The goal of the program is to accelerate the advancement of promising early-stage therapeutic candidates and facilitate their readiness for Phase II clinical trials. Applicants must have a promising small molecule or biologic lead candidate for optimization, a strong biological rationale for the proposed approach, and established assays to guide the optimization process. The scope of the program includes lead optimization, early-stage development activities, IND-enabling studies, development of pharmacodynamic and/or target engagement biomarkers, preparation and submission of an Investigational New Drug (IND) application, and Phase I clinical testing. This is a milestone-driven, phased cooperative agreement program that involves active participation by NIH program staff in project planning and ongoing monitoring of research progress.

Let AI draft your application

Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.

Application Kit — $49 one-time

Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.

Get the Application Kit

Related grants

Other open grants funding Health — soonest deadline first.

Also listed under National Institutes of Health and Health Grants.

Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.